Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Rhinomed Limited (ASX: RNO)

ABN

12 107 903 159

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of \*securities issued or to be issued

**Unlisted Options** 

- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- a) 10,000,000 Unlisted Options
- b) 3,000,000 Unlisted Options
- 3 Principal terms of the

  \*securities (e.g. if
  options, exercise price
  and expiry date; if
  partly paid \*securities,
  the amount
  outstanding and due
  dates for payment; if

  \*convertible securities,
  the conversion price
  and dates for
  conversion)
- a) 10,000,000 Unlisted Options exercisable at \$0.2998, expiring 29 November 2023
- a) 3,000,000 Unlisted Options excercisable at \$0.2998, expiring 20 January 2024

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all a & b) No, the Unlisted Options are new classes respects from the +issue date with of securities and may only be excercised in an existing +class of quoted accordance with their terms and conditions. On \*securities? exercise, the shares issued will rank equally with exixting quoted shares. If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment a & b) Nil 5 Issue price or consideration 6 Purpose of the issue Issue of Unlisted Options pursuant to (If issued as consideration for Resolutions 6, 7, 8 and 9 as approved by the acquisition of assets, clearly shareholders at the Annual General identify those assets) meeting held on 29 November 2019 b) Issue of Unlisted Options under Long Term Incentive Plan (LTIP) 6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was 29 November 2019 passed 6c Number of \*securities issued Nil without security holder approval under rule 7.1 6d Number of \*securities issued Nil with security holder approval

under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- a) 10,000,000 Unlisted Options
- 6f Number of \*securities issued under an exception in rule 7.2
- b) 3,000,000 Unlisted Options
- 6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.

N/A

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Refer to the attached Annexure 1

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

a & b) 24 January 2020

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	†Class
169,206,016	Fully Paid Ordinary Shares (RNO)

<sup>+</sup> See chapter 19 for defined terms.

1 1

		Number	
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	6,000,000 9,000,000	
		150,000	

Number	<sup>+</sup> Class
6,000,000	Unlisted Options exercisable at \$0.27, expiring 30 April 2020
9,000,000	Unlisted Options exercisable at \$0.287, expiring 21 December 2021
150,000	Unlisted Options exercisable at \$0.40, expiring 30 December 2020
13,000,000	Unlisted Options exercisable at \$0.2998, expiring 29 November 2023

Dividend policy (in the case of a 10 trust, distribution policy) on the increased capital (interests)

Unchanged

#### Part 2 - Pro rata issue - n/a

Is security holder approval N/A 11 required?

12 Is the issue renounceable or nonrenounceable?

N/A

13 Ratio in which the +securities will be offered

N/A

14 \*Class of \*securities to which the offer relates

N/A

15 <sup>+</sup>Record date to determine entitlements

N/A

16 Will holdings different on registers (or subregisters) be aggregated for calculating entitlements?

N/A

Policy for deciding entitlements 17 in relation to fractions

N/A

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
00	Name of the last of the	T.,,,
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on	N/A
20	security holders' approval, the date of the meeting	IV/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options,	N1/A
21	and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if	N/A
20	applicable)	19/0
29	Date rights trading will end (if applicable)	N/A

<sup>+</sup> See chapter 19 for defined terms.

30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A
	3 - Quotation of sector of sector of section	
34	(tick one)	
(a)	*Securities described in Pa	rt 1
(b)		of the escrowed period, partly paid securities that become fully paid, employ a ends, securities issued on expiry or conversion of convertible securities
Entiti	es that have ticked box 34	4(a)
	onal securities forming a new indicate you are providing the informati	
35		y securities, the names of the 20 largest holders of and the number and percentage of additionablers
36		y securities, a distribution schedule of the additional umber of holders in the categories
37	A copy of any trust deed for	r the additional <sup>+</sup> securities
	es that have ticked box 34 on 38 to 42 – Not Applicable	4(b)

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation Agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act 
  at the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before \*quotation of the \*securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 28 January 2020

Sign here:

1

Company Secretary

Print name: Phillip Hains

+ See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	141,933,281
Add the following:	
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	27,272,735
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid *ordinary securities that became fully paid in that 12 month period	
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	
Subtract the number of fully paid  †ordinary securities cancelled during that 12 month period	-
"A"	169,206,016

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
	25,380,902
Multiply "A" by 0.15	
Step 3: Calculate "C", the amount of place already been used	cement capacity under rule 7.1 that has
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
<ul> <li>Under an exception in rule 7.2</li> </ul>	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15	25,380,902
Note: number must be same as shown in Step 2	
Subtract "C"	
Note: number must be same as shown in Step 3	
	25,380,902

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	169,206,016	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	16,920,601	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	_	
"E"	_	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	16,920,601
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	16,920,601
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.